FY2025 EPS Estimates for Q32 Bio Cut by Leerink Partnrs

Q32 Bio Inc. (NASDAQ:QTTB) – Investment analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Q32 Bio in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($4.37) per share for the year, down from their prior estimate of ($3.38). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. Leerink Partnrs also issued estimates for Q32 Bio’s FY2026 earnings at ($3.09) EPS, FY2027 earnings at ($3.59) EPS and FY2028 earnings at ($2.47) EPS.

Several other research analysts have also recently issued reports on the company. Wells Fargo & Company reiterated an “equal weight” rating and issued a $16.00 price objective (down previously from $95.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Piper Sandler reduced their price objective on shares of Q32 Bio from $85.00 to $20.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Leerink Partners reissued a “market perform” rating and set a $9.00 price objective (down previously from $68.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Oppenheimer reduced their price target on shares of Q32 Bio from $80.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Finally, BMO Capital Markets lowered their price target on Q32 Bio from $64.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

Q32 Bio Stock Up 1.0 %

QTTB opened at $3.18 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. Q32 Bio has a 12 month low of $2.90 and a 12 month high of $53.79. The stock has a market capitalization of $38.73 million, a P/E ratio of -0.22 and a beta of -0.32. The business has a 50 day simple moving average of $6.39 and a 200-day simple moving average of $29.02.

Hedge Funds Weigh In On Q32 Bio

Several hedge funds have recently bought and sold shares of QTTB. Monaco Asset Management SAM acquired a new stake in shares of Q32 Bio during the fourth quarter valued at $1,977,000. FMR LLC raised its stake in Q32 Bio by 137.3% during the third quarter. FMR LLC now owns 426,302 shares of the company’s stock worth $19,022,000 after purchasing an additional 246,664 shares during the period. Eventide Asset Management LLC acquired a new stake in shares of Q32 Bio during the 3rd quarter worth $8,478,000. Geode Capital Management LLC raised its position in shares of Q32 Bio by 22.4% in the 3rd quarter. Geode Capital Management LLC now owns 131,768 shares of the company’s stock worth $5,881,000 after buying an additional 24,114 shares during the period. Finally, State Street Corp boosted its holdings in Q32 Bio by 35.5% in the third quarter. State Street Corp now owns 110,164 shares of the company’s stock valued at $4,916,000 after acquiring an additional 28,865 shares during the last quarter. Hedge funds and other institutional investors own 31.32% of the company’s stock.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.